| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
|
N Engl J Med
|
2009
|
10.54
|
|
2
|
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
|
Nature
|
2012
|
9.89
|
|
3
|
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
|
Blood
|
2008
|
5.49
|
|
4
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
5
|
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.
|
J Clin Oncol
|
2012
|
5.08
|
|
6
|
JAK mutations in high-risk childhood acute lymphoblastic leukemia.
|
Proc Natl Acad Sci U S A
|
2009
|
4.98
|
|
7
|
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
|
Nat Genet
|
2011
|
4.93
|
|
8
|
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
|
Cancer Cell
|
2012
|
4.41
|
|
9
|
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
|
J Clin Oncol
|
2009
|
4.20
|
|
10
|
Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.
|
Blood
|
2010
|
4.00
|
|
11
|
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
|
Blood
|
2006
|
3.91
|
|
12
|
Germline genomic variants associated with childhood acute lymphoblastic leukemia.
|
Nat Genet
|
2009
|
3.71
|
|
13
|
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
|
Blood
|
2010
|
3.66
|
|
14
|
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
Nat Genet
|
2013
|
3.43
|
|
15
|
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2011
|
3.40
|
|
16
|
Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.
|
J Clin Oncol
|
2003
|
3.21
|
|
17
|
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
|
Blood
|
2009
|
2.86
|
|
18
|
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
|
JAMA
|
2009
|
2.72
|
|
19
|
Outcomes after induction failure in childhood acute lymphoblastic leukemia.
|
N Engl J Med
|
2012
|
2.60
|
|
20
|
Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
|
Lancet Oncol
|
2012
|
2.46
|
|
21
|
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
|
J Clin Oncol
|
2009
|
2.44
|
|
22
|
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2012
|
2.09
|
|
23
|
Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).
|
Blood
|
2011
|
2.04
|
|
24
|
Survivors of standard risk acute lymphoblastic leukemia do not have increased risk for overweight and obesity compared to non-cancer peers: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2015
|
2.02
|
|
25
|
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
|
Blood
|
2007
|
1.97
|
|
26
|
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.90
|
|
27
|
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
|
J Clin Oncol
|
2008
|
1.83
|
|
28
|
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
|
J Natl Cancer Inst
|
2013
|
1.81
|
|
29
|
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.79
|
|
30
|
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2005
|
1.76
|
|
31
|
Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
|
J Clin Oncol
|
2005
|
1.70
|
|
32
|
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
|
Blood
|
2010
|
1.67
|
|
33
|
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
|
J Clin Oncol
|
2009
|
1.58
|
|
34
|
Functional outcome after thoracoabdominal aortic aneurysm repair.
|
J Vasc Surg
|
2002
|
1.48
|
|
35
|
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
|
Blood
|
2012
|
1.47
|
|
36
|
Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.
|
Leuk Res
|
2010
|
1.46
|
|
37
|
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
|
Nat Genet
|
2013
|
1.45
|
|
38
|
Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research.
|
Blood
|
2006
|
1.44
|
|
39
|
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2012
|
1.39
|
|
40
|
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2011
|
1.39
|
|
41
|
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.
|
Br J Haematol
|
2008
|
1.34
|
|
42
|
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
|
Pediatr Blood Cancer
|
2011
|
1.33
|
|
43
|
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
|
J Clin Oncol
|
2006
|
1.30
|
|
44
|
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2012
|
1.29
|
|
45
|
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.
|
J Clin Oncol
|
2012
|
1.27
|
|
46
|
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2011
|
1.25
|
|
47
|
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
|
J Clin Oncol
|
2002
|
1.22
|
|
48
|
Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2012
|
1.20
|
|
49
|
Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2007
|
1.19
|
|
50
|
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2008
|
1.18
|
|
51
|
Genome-wide study of methotrexate clearance replicates SLCO1B1.
|
Blood
|
2012
|
1.17
|
|
52
|
Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.
|
J Clin Oncol
|
2006
|
1.17
|
|
53
|
Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy.
|
Ann Surg
|
2003
|
1.14
|
|
54
|
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2010
|
1.13
|
|
55
|
Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial.
|
J Clin Oncol
|
2007
|
1.13
|
|
56
|
Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia.
|
Genome Res
|
2012
|
1.11
|
|
57
|
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
|
J Clin Oncol
|
2013
|
1.07
|
|
58
|
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2008
|
1.05
|
|
59
|
Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.
|
Blood
|
2010
|
1.00
|
|
60
|
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
|
Blood
|
2013
|
0.99
|
|
61
|
Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups.
|
Eur J Cancer
|
2010
|
0.96
|
|
62
|
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2013
|
0.96
|
|
63
|
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
|
Blood
|
2013
|
0.95
|
|
64
|
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
|
Pediatr Blood Cancer
|
2006
|
0.94
|
|
65
|
Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.
|
J Clin Oncol
|
2008
|
0.93
|
|
66
|
Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.
|
Pediatr Blood Cancer
|
2012
|
0.93
|
|
67
|
A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Cancer
|
2014
|
0.92
|
|
68
|
Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group.
|
Cancer
|
2014
|
0.90
|
|
69
|
Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples.
|
Clin Cancer Res
|
2003
|
0.87
|
|
70
|
Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Clin Cancer Res
|
2007
|
0.87
|
|
71
|
TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2014
|
0.85
|
|
72
|
Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
J Pediatr Hematol Oncol
|
2007
|
0.85
|
|
73
|
Family life events in the first year of acute lymphoblastic leukemia therapy: a children's oncology group report.
|
Pediatr Blood Cancer
|
2014
|
0.85
|
|
74
|
Germline genetic variation and treatment response on CCG-1891.
|
Pediatr Blood Cancer
|
2011
|
0.84
|
|
75
|
Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study.
|
Cancer Genet
|
2012
|
0.83
|
|
76
|
Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9).
|
J Pediatr Hematol Oncol
|
2013
|
0.83
|
|
77
|
Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.
|
Cancer Genet Cytogenet
|
2007
|
0.82
|
|
78
|
Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study.
|
J Pediatr Hematol Oncol
|
2006
|
0.81
|
|
79
|
Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).
|
Pediatr Blood Cancer
|
2014
|
0.80
|
|
80
|
Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group.
|
Br J Haematol
|
2014
|
0.80
|
|
81
|
Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics.
|
Leuk Lymphoma
|
2008
|
0.80
|
|
82
|
Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
J Pediatr Hematol Oncol
|
2012
|
0.79
|
|
83
|
Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.
|
J Pediatr Hematol Oncol
|
2014
|
0.79
|
|
84
|
Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.
|
Pediatr Blood Cancer
|
2014
|
0.78
|
|
85
|
Does intravenous 6-mercaptopurine decrease salvage after relapse in childhood acute lymphoblastic leukemia?
|
Pediatr Blood Cancer
|
2006
|
0.77
|
|
86
|
Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: a Children's Oncology Group Study (POG 8764).
|
J Pediatr Hematol Oncol
|
2013
|
0.77
|
|
87
|
Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.
|
Cancer Chemother Pharmacol
|
2014
|
0.76
|
|
88
|
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
|
J Pediatr Hematol Oncol
|
2016
|
0.75
|
|
89
|
One- and two-stage designs for phase II window studies.
|
Stat Med
|
2007
|
0.75
|
|
90
|
Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method.
|
Br J Haematol
|
2006
|
0.75
|